Emergent BioSolutions

This study will evaluate how well the drug raxibacumab works and how safe it is for people who have symptoms of inhalational anthrax after a large-scale exposure, such as a bioterrorist attack. Up to 100 people of all ages, including pregnant women and children, who receive the d…

This study follows up to 10 people with severe anthrax who receive a treatment called AIGIV. Researchers will track how many patients survive and whether the drug causes serious side effects. The goal is to learn more about how well AIGIV works and how it behaves in the body.

This study will test a medicine called AIGIV for people who have breathed in anthrax germs during a large-scale emergency. The goal is to see if the drug helps more people survive and to check for side effects. The study will only start if a major anthrax event happens, and it wi…

This study will look at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria during a mass event. Researchers want to see if the vaccine, given along with antibiotics, can prevent inhalational anthrax and anthrax meningitis. The study is ob…

This observational study will follow up to 10 people in the U.S. who have a confirmed case of systemic anthrax and are treated with the drug raxibacumab. Researchers will track survival, side effects, and drug levels in the blood to better understand how well the treatment works.…